{"url_path":"/sec/orka/8-k/2026-06-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/907654/0001213900-26-063481-index.html","accession_number":"0001213900-26-063481","cik":"0000907654","ticker":"ORKA","issuer_name":"Oruka Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/907654/0001213900-26-063481-index.html","primary_entity_key":"0000907654","primary_entity_name":"Oruka Therapeutics, Inc."},"word_count":85,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n \n**Description**\n\n10.1\n \n[First Amendment to IL-23 License Agreement, dated May 29, 2026](ea029287601ex10-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n1\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**Oruka Therapeutics, Inc.**\n\n \n(Registrant)\n\n \n \n \n\nDate: June 1, 2026\nBy:\n/s/ Paul Quinlan\n\n \n \nName:\nPaul Quinlan\n\n \n \nTitle:\nGeneral Counsel\n\n \n\n2"}